Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. The compelling preclinical efficacy and safety of ONC201 along with its favorable chemical properties offer a high potential for safe and meaningful therapeutic benefit to cancer patients in numerous clinical settings. Clinical lead indications for ONC201 are being evaluated in a series of clinical trials that are in various stages of initiation at leading cancer centers around the world.

Senior Management

Wolfgang Oster
Chief Executive Officer

Wolfgang Oster, M.D., Ph.D. is board certified in internal medicine, hematology/oncology, and served as Adjunct Professor at Brown University. For 25 years he has worked in the Life Science Industry as an executive, investor and entrepreneur. Dr. Oster was responsible for leading 9 Marketing Authorization Applications to successful global approvals. As an investor, several of his companies accomplished market introductions or major development inflection points leading to a total of 2 major trade sales and 5 IPOs.
Lee Schalop
Chief Business Officer

Lee Schalop, M.D. is the company’s chief business officer, a role he has held since graduating with a doctor of medicine degree from the Albert Einstein College of Medicine in 2008. Prior to attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of Banc of America Securities.
Martin Stogniew
Chief Development Officer

Martin Stogniew, Ph.D. brings 32 years of senior executive experience in the pharmaceutical industry and has served as an independent member of the Board of Directors for Provid Pharmaceuticals. Dr. Stogniew has made significant contributions resulting in FDA approval of 8 New Drug Applications, issuance of 27 US patents, and closure of 4 major M&A deals totaling ~3 billion dollars.
Joshua Allen
Vice President - Development

Joshua Allen, Ph.D. is the co-inventor of ONC201 who discovered the drug in the lab and possesses a deep technical knowledge of the product and field. Dr. Allen is an experienced cancer researcher with a proven capacity to design, execute and manage translational scientific studies that have resulted in clinical and commercial engagement in oncology.

Contact Us

Full Name(require)

News and Updates

Proprietary Discovery Method for First-in-class ONC201 Published

Hummelstown, PA (May 05, 2015) – Oncoceutics, Inc. announced publication of a research article in the journal Molecular Cancer, which describes the discovery of ONC201 as a selective lead compound with a novel chemical structure and novel mechanism of action that warranted clinical testing. In an attempt to identify inducers of tumor cell death that […]

Oncoceutics Awarded NCI Grant for Clinical Trial of ONC201 in GBM

Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc. announced that the company was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The combined Phase I/II Fast Track grant will support a clinical trial in ONC201 in advanced brain cancer, furthering the clinical development of the company’s lead compound. ONC201 […]

ONC201 Featured in Seven Abstracts at 2015 AACR Meeting

Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for […]

Rutgers Cancer Institute of New Jersey Starts ONC201 Clinical Trials; Phase I Trials Begin on Oncoceutics’ First-in-Class Therapy

Hummelstown, PA (March 03, 2015) – Oncoceutics, Inc. is pleased to report that enrollment of the first patient in a clinical trial of ONC201, a novel small molecule anti-cancer drug, is now taking place at Rutgers Cancer Institute of New Jersey. The trial, identified as NCT02250781 on www.clinicaltrials.gov, is entitled “Oral ONC201 in Treating Patients […]